# Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

> **NCT04452591** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CG Oncology, Inc.** · enrollment: 190 (estimated)

## Conditions studied

- Non Muscle Invasive Bladder Cancer
- High-grade Ta/ T1 Papillary Disease Bladder Cancer

## Interventions

- **BIOLOGICAL:** Cretostimogene Grenadenorepvec
- **OTHER:** n-dodecyl-B-D-maltoside

## Key facts

- **NCT ID:** NCT04452591
- **Lead sponsor:** CG Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-27
- **Primary completion:** 2030-06-16
- **Final completion:** 2031-12-24
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452591, "Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04452591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*